Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Modified VR-CAP and Acalabrutinib as First Line Therapy for Mantle Cell Lymphoma
NCT04626791Phase 2Active, not recruiting
- Sponsor
- Academic and Community Cancer Research United
- Start
- Aug 2021
- Primary completion
- Aug 2025
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of acalabrutinib tablet (Variant 1) in mantle cell lymphoma (MCL), sponsored by Academic and Community Cancer Research United. Primary endpoint: Complete Metabolic Response at 29 months. Started Aug 2021; status: active, not recruiting.
02
Drugs
acalabrutinib tablet (Variant 1)
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT04626791.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04626791.